The Body Covers:
The 41st Interscience Conference on Antimicrobial Agents and Chemotherapy
McCormick Place Lakeside Center, Chicago, Illinois

December 16-19, 2001

The Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) -- an annual meeting of the American Society for Microbiology -- is the major international meeting on antimicrobial agents and infectious diseases.

In addition to its scientific symposia, the conference includes special lectures, slide sessions, poster presentations, minilectures, meet-the-experts roundtables, and interactive sessions. Complementing the invited sessions are abstract sessions, which allow for the presentation of new and significant developments in therapy, prevention, pathogenesis, epidemiology, immunology and diagnosis of both established and emerging infectious diseases. To view the ICAAC program and website, click here:

The Body's next-day conference summaries will be reported exclusively by some of the most outstanding HIV specialists in the U.S.A.: Brian Boyle, M.D., J.D., Cal Cohen, M.D., M.S., Edwin DeJesus, M.D., Doug Dieterich, M.D., Alvan Fisher, M.D., Bob Frascino, M.D., Mark Holodniy, M.D., Andy Pavia, M.D., Maribel Rodriguez-Torres, M.D. and Paul Sax, M.D.

Funding for this conference coverage at The Body is provided, in part, by unrestricted educational grants from Bio-Technology General Corp., Boehringer Ingelheim Pharmaceuticals, Bristol-Myers Squibb Virology, GlaxoSmithKline and Ortho Biotech, Inc.

The Body's Conference Summaries
Day One
December 16
Day Two
December 17
Day Three
December 18
Day Four
December 19

Implications of Anemia: Focus on Managing Patients Infected with HIV and HCV

Select HIV Protease Inhibitors Alter Bone and Fat Metabolism In Vitro

Triglyceride Increase Can Predict Lipodystrophy in HIV Patients Under HAART

Comparison of Nevirapine Resistance Mutations in Women vs. Infants Receiving Single Dose NVP Prophylaxis to Prevent HIV-1 Vertical Transmission (HIVNET 012)

Once-Weekly Dosing of 40,000 U Epoetin Alpha Is as Effective as Thrice-Weekly Dosing Among HIV-Positive Patients

Use of Structured Treatment Interruptions in Primary Infections

STI in Patients with Incomplete Viral Suppression

Therapeutic Vaccinations

Pathogenesis of Hepatitis C Virus (HCV) in HIV-Positive Patients

Evaluation of Two Doses of Peginterferon Alfa-2a for the Treatment of Chronic Hepatitis C

Amprenavir Plasma and Intracellular Concentrations When Co-Administered with Ritonavir in Twice- and Once-Daily Regimens in HIV-Infected Patients

Effect of Food on Oral Bioavailability of Didanosine from Delayed Release Capsules Containing Enteric Coated Beads

Population Pharmacodynamic Assessment of the Safety and Antiretroviral Activity of BMS-232632

Tenofovir DF: A 24-Week Interim Analysis from a Phase III Double-Blind, Placebo-Controlled Study in Antiretroviral-Experienced Patients

Comparative Results (Phase II 48-Week): BMS-232632, Stavudine, Lamivudine as HAART for Treatment-Naive HIV-Positive Patients (AI424-008)

TMC125 Is a Highly Potent Non-Nucleoside Reverse Transcriptase Inhibitor in Antiretroviral Therapy-Naive, HIV-1 Infected Subjects

Genotypic Resistance to Protease and Reverse Transcriptase Inhibitors and Antiretroviral History Do Not Affect Virologic Response to T-1249

Switch to Trizivir Versus Continued HAART Provides Equivalent HIV-1 RNA Suppression at 48 Weeks (TRIZAL - AZL30002)

Pancreatitis: An Emerging Complication of HCV Treatment in HIV Co-Infected Patients Treated with Didanosine/Stavudine Containing Regimens

HIV-Specific Cellular Immune Responses in Patients with Immunologic Control of Viral Replication

Management of "Salvage" Antiretroviral Therapy

Emerging Complications of HIV Therapy

The ENVA-3 World Wide Evaluation Study Shows Extensive Differences in Interpretation on HIV-1 Genotype Analysis

Assessing the Teratogenic Potential of Antiretroviral Drugs: Data from the Antiretroviral Pregnancy Registry

Risks for Cardiovascular Disease Associated with Antiretroviral Therapy

Safety and Efficacy of Tipranavir, a Novel Non-Peptidic Protease Inhibitor, Plus Ritonavir in PI-Failure Patients

Once-Daily Atazanavir Plus Saquinavir Favorably Affects Total Cholesterol and Fasting Triglyceride Profiles in Patients Failing Prior PI Therapy (Trial AI424-009, Week 24)

The Prevalence of Antiretroviral Drug Resistance in the U.S.

Prognosis of HIV-1 Infected Drug-Naive Patients Starting Potent Antiretroviral Therapy: Multi-Cohort Analysis of 12,040 Patients

Metabolic Complications of HIV Disease

An Assessment of Plasma Amprenavir Pharmacokinetics Following Administration of Two GW433908 and Ritonavir QD Regimens in Combination with Efavirenz in Healthy Adult Subjects (APV10009)

Virologic Response to Antiretroviral Therapy in Chronically HIV-1-Infected, Antiretroviral-Naive Adults with Baseline Genotypic Resistance

Impact of M184V/I Mutation on HIV Phenotypic Resistance to Nucleoside Analogs in NRTI-Experienced Patients

Diverse Effects of NRTI-Associated Mutations on Resistance to Abacavir, Stavudine and Zidovudine in the ZORRO Trial

Variations in HIV-1 Gag p6 Contribute to the Amprenavir-Specific Protease I50V Resistance Pathway

Impact on Fitness Conferred by Amprenavir Resistance Mutations

Discontinuation of Maintenance Therapy for Cytomegalovirus Retinitis in HIV-Infected Patients Who Have Responded to Highly Active Antiretroviral Therapy

Structured Treatment Interruptions in Patients Receiving HAART Since Primary HIV-1 Infection: Spontaneous Control of Viremia in Almost Half of Cases After the First Two Cycles Off Therapy

Predictors of Virologic and Immunologic Success Post Treatment Interruption in Patients with Chronic HIV Infection

Long-Term Effects of Treatment Interruptions: 18-Month Evaluation of a Controlled Trial in >300 HIV-Positive Patients

Long-Term Outcome of Naive HIV-Infected Patients with Small Increases in CD4+ Cells After Successful Virological Suppression: A Study of Discordant Responses with HAART

Clinical and Immunological Outcomes in Severely Immunosuppressed Naive Patients on Effective Protease Inhibitor-Based HAART

Modeling the Impact of Revised DHHS HIV Treatment Guidelines on Survival in Women

Once-Daily vs. Twice-Daily Directly Observed Therapy for Management of HIV-Infected Individuals in a Methadone Program

Virologic Response to Abacavir/Efavirenz/ddI + Hydroxyurea in Subjects Failing Initial NRTI + PI Therapy (NZTA4008 Study)

Efficacy, Safety and Amprenavir: Pharmacokinetic Responses of Twice-Daily Amprenavir and Ritonavir Regimens in HIV-1 Infected Treatment-Experienced Adults for 48 Weeks (ESS40006)

Long-Term Efficacy and Safety of Emtricitabine in HIV-Positive Adults Switching from a Lamivudine-Containing HAART Regimen

Accumulation of DC-SIGN+ CD40+ Dendritic Cells with Reduced CD80 and CD86 Expression in Lymphoid Tissue During Acute HIV-1 Infection

In Vitro Model for Antiviral Activity for Amprenavir/Ritonavir

Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.